Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer

Kenji Kuroda, Yutaka Horiguchi, Jun Nakashima, Eiji Kikuchi, Kent Kanao, Akira Miyajima, Takashi Ohigashi, Kazuo Umezawa, Masaru Murai

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor κB (NF-κB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer. Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer. Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05). Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-κB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.

Original languageEnglish
Pages (from-to)5590-5594
Number of pages5
JournalClinical Cancer Research
Volume11
Issue number15
DOIs
Publication statusPublished - 2005 Aug 1

Fingerprint

Cachexia
Interleukin-6
Prostatic Neoplasms
Neoplasms
Serum
Hormones
Weights and Measures
Dimethyl Sulfoxide
dehydroxymethylepoxyquinomicin
Hematocrit
Albumins
Skeletal Muscle
Triglycerides
Research Design
Animal Models
Fats
Body Weight

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kuroda, K., Horiguchi, Y., Nakashima, J., Kikuchi, E., Kanao, K., Miyajima, A., ... Murai, M. (2005). Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. Clinical Cancer Research, 11(15), 5590-5594. https://doi.org/10.1158/1078-0432.CCR-04-2561

Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. / Kuroda, Kenji; Horiguchi, Yutaka; Nakashima, Jun; Kikuchi, Eiji; Kanao, Kent; Miyajima, Akira; Ohigashi, Takashi; Umezawa, Kazuo; Murai, Masaru.

In: Clinical Cancer Research, Vol. 11, No. 15, 01.08.2005, p. 5590-5594.

Research output: Contribution to journalArticle

Kuroda, K, Horiguchi, Y, Nakashima, J, Kikuchi, E, Kanao, K, Miyajima, A, Ohigashi, T, Umezawa, K & Murai, M 2005, 'Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer', Clinical Cancer Research, vol. 11, no. 15, pp. 5590-5594. https://doi.org/10.1158/1078-0432.CCR-04-2561
Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A et al. Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. Clinical Cancer Research. 2005 Aug 1;11(15):5590-5594. https://doi.org/10.1158/1078-0432.CCR-04-2561
Kuroda, Kenji ; Horiguchi, Yutaka ; Nakashima, Jun ; Kikuchi, Eiji ; Kanao, Kent ; Miyajima, Akira ; Ohigashi, Takashi ; Umezawa, Kazuo ; Murai, Masaru. / Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 15. pp. 5590-5594.
@article{284e653883704a649470bf3760d75722,
title = "Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer",
abstract = "Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor κB (NF-κB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer. Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer. Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05). Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-κB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.",
author = "Kenji Kuroda and Yutaka Horiguchi and Jun Nakashima and Eiji Kikuchi and Kent Kanao and Akira Miyajima and Takashi Ohigashi and Kazuo Umezawa and Masaru Murai",
year = "2005",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-04-2561",
language = "English",
volume = "11",
pages = "5590--5594",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer

AU - Kuroda, Kenji

AU - Horiguchi, Yutaka

AU - Nakashima, Jun

AU - Kikuchi, Eiji

AU - Kanao, Kent

AU - Miyajima, Akira

AU - Ohigashi, Takashi

AU - Umezawa, Kazuo

AU - Murai, Masaru

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor κB (NF-κB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer. Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer. Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05). Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-κB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.

AB - Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor κB (NF-κB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer. Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer. Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05). Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-κB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=23044483988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044483988&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2561

DO - 10.1158/1078-0432.CCR-04-2561

M3 - Article

VL - 11

SP - 5590

EP - 5594

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -